CGBio (CEO Hyun Seung Yu), specializing in bio regenerative medicine, announced on the 17th that it will apply for a permit for its premium hyaluronic acid (HA) filler, GISELLELIGNE in the six member countries of Gulf Cooperation Council (GCC) to enter the Middle Eastern markets.

GISELLELIGNE has established its presence in East Asia markets such as Indonesia and Vietnam, starting with China, the world’s largest filler market. Now, the company is venturing into the Middle Eastern markets for the first time.

Last year, the company signed two export deals worth KRW10 billion and KRW20 billion, respectively, for its calcium (CaHA) filler Facetem and HA filler AiLEENE and GISELLELIGNE for a three year supply to the Middle East. Consequently, if the permit for GISELLELIGNE is granted, the company’s all filler lines for export will have successfully entered the Middle Eastern markets.

GISELLELIGNE is CGBio’s premium HA filler that combines the benefits of biphasic filler, which can add volume and definition with high elasticity, and monophasic filler, which can produce a natural look with high viscosity. It is the world’s first multi-layered phasic filler made by mixing two high viscosity forms in a specific ratio through revolution and rotation. It features well-defined volume and a seamless look at the injection spots.

For rapid entry into the Middle East, CGBio undertook separate measures in addition to the permit application: it made a 20 billion export contract with Karma Cosmetics Company, the leading medical device distributer in the region, for a three year supply of Giselleligne and Aileene fillers, and has completed preparations for local distribution.

The response to GISELLELIGNE has been positive among medical professionals. Dr. Mark Mckelvie, who has extensive clinical experiences in using GISELLELIGNE in the UK said, “It combines just the benefits of biphasic filler and monophasic filler, so it stays in place better than other types of fillers and is easier to add volume and definition to the satisfaction of patients. It also has evenly distributed particles, which makes it gentle on the skin and easy to sculpt. It’s quite satisfactory among medical professionals, as well”

Mark Mckelvie is one of the rising young key opinion leaders (KOL) in the global filler industry. He is not just known for his extensive experiences in using GISELLELIGNE, but also his hands-on expertise in harnessing advanced fillers within the European filler markets and integrating them into clinical applications.

Mark Mckelvie also met with Jae Yoon Jung (head of Oaro Dermatology), a KOL in Korea’s filler procedure industry, to discuss the characteristics of different types of fillers and various applications of GISELLELIGNE based on his clinical experiences as DNC Aesthetics, a CGBio’s subsidiary specializing in aesthetic, has recently begun domestic sales in full swing. The discourse will be uploaded on the official Youtube channel of CGBio.

CGBio CEO Hyun Seung Yu said, “The advance of GISELLELIGNE into the Middle East is a positive sign that it can continue to expand into other continents beyond the East Asian markets that have been our focus.”, adding, “In the second half of this year, we will successfully renew our other HA filler, VOM filler and carry out aggressive sales marketing campaigns for both VOM and GISELLELIGNE which is currently being sold in Korea”